170 related articles for article (PubMed ID: 16430475)
1. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions.
Cho Mar K; Eimoto T; Tateyama H; Arai Y; Fujiyoshi Y; Hamaguchi M
Histopathology; 2006 Feb; 48(3):286-94. PubMed ID: 16430475
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
3. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
[TBL] [Abstract][Full Text] [Related]
4. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
5. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
6. Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid.
Cho Mar K; Eimoto T; Nagaya S; Tateyama H
Histopathology; 2006 Jun; 48(7):801-7. PubMed ID: 16722928
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling.
Zhao J; Leonard C; Gemsenjäger E; Heitz PU; Moch H; Odermatt B
Oncol Rep; 2008 Feb; 19(2):329-37. PubMed ID: 18202778
[TBL] [Abstract][Full Text] [Related]
8. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
9. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.
de Vicente JC; Lequerica-Fernández P; Santamaría J; Fresno MF
J Oral Pathol Med; 2007 Aug; 36(7):415-24. PubMed ID: 17617835
[TBL] [Abstract][Full Text] [Related]
10. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds.
Impola U; Jeskanen L; Ravanti L; Syrjänen S; Baldursson B; Kähäri VM; Saarialho-Kere U
Br J Dermatol; 2005 Apr; 152(4):720-6. PubMed ID: 15840104
[TBL] [Abstract][Full Text] [Related]
13. [Expression of MMPPs and TIMP and invasiveness in pituitary adenomas].
Wang J; Liu YS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):647-50. PubMed ID: 16114548
[TBL] [Abstract][Full Text] [Related]
14. p53 protein, PCNA staining, and DNA content in follicular neoplasms of the thyroid gland.
Czyz W; Joensuu H; Pylkkänen L; Klemi PJ
J Pathol; 1994 Dec; 174(4):267-74. PubMed ID: 7884588
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
19. Activation ratio of MMP-2 and expression of MT1-MMP are correlated in thymic epithelial tumours.
Wang Y; Xu HT; Ueda Y; Shimasaki M; Wang EH
Pathology; 2007 Oct; 39(5):486-90. PubMed ID: 17886098
[TBL] [Abstract][Full Text] [Related]
20. Matrix-metalloproteinases in Hodgkin lymphoma.
Thorns C; Bernd HW; Hatton D; Merz H; Feller AC; Lange K
Anticancer Res; 2003; 23(2B):1555-8. PubMed ID: 12820423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
